KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

AbbVie (ABBV) EBIAT (2016 - 2025)

AbbVie (ABBV) has disclosed EBIAT for 14 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT rose 5980.65% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 billion, a 1.12% decrease, with the full-year FY2025 number at $4.2 billion, down 1.05% from a year prior.
  • EBIAT was $1.8 billion for Q4 2025 at AbbVie, up from $183.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $4.5 billion in Q1 2022 to a low of -$31.0 million in Q4 2024.
  • A 5-year average of $1.8 billion and a median of $1.5 billion in 2024 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: surged 11150.0% in 2021, then tumbled 103.77% in 2024.
  • AbbVie's EBIAT stood at $4.0 billion in 2021, then tumbled by 38.94% to $2.5 billion in 2022, then tumbled by 66.76% to $822.0 million in 2023, then crashed by 103.77% to -$31.0 million in 2024, then skyrocketed by 5980.65% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBIAT are $1.8 billion (Q4 2025), $183.0 million (Q3 2025), and $938.0 million (Q2 2025).